Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Kaiser

Showing results (41-50 of 160) with videos related to

Pageof 16
Sort By:
Experimental Cell Research|May 5, 2009
Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myelomaIvana von Metzler, Ulrike Heider, Maren Mieth, et al.
Organic Letters|December 1, 2006
New synthetic protocols for the preparation of unsymmetrical bisindolesHanns Martin Kaiser, Wei Fun Lo, Abdol Majid Riahi, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2006
Angiogenesis in multiple myelomaChristian Jakob, Jan Sterz, Ivana Zavrski, et al.
Organic Letters|July 28, 2007
A general copper-catalyzed sulfonylation of arylboronic acidsAnirban Kar, Iliyas Ali Sayyed, Wei Fun Lo, et al.
BMJ Open|October 26, 2022
MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myelomaJessica Kendall, Andrew Hall, Sadie Roberts, et al.
Haematologica|February 8, 2006
The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myelomaMartin Kaiser, Ivana Zavrski, Jan Sterz, et al.
Annals of Human Genetics|February 16, 2019
Regions of homozygosity as risk factors for multiple myelomaMolly Went, Amit Sud, Ni Li, et al.
The British Journal of Radiology|March 18, 2021
Repeatability and reproducibility of apparent diffusion coefficient and fat fraction measurement of focal myeloma lesions on whole body magnetic resonance imagingTara Barwick, Matthew Orton, Dow Mu Koh, et al.
British Journal of Haematology|January 18, 2021
A real-world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple-myeloma patientsSarah Bird, Charlotte Pawlyn, Susanna Nallamilli, et al.
BMC Cancer|April 2, 2020
Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myelomaPriya Sriskandarajah, Alexis De Haven Brandon, Kenneth MacLeod, et al.
Pageof 16

Showing results (41-50 of 160) with videos related to

Sort By:
Pageof 16
Experimental Cell Research|May 5, 2009
Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myelomaIvana von Metzler, Ulrike Heider, Maren Mieth, et al.
Organic Letters|December 1, 2006
New synthetic protocols for the preparation of unsymmetrical bisindolesHanns Martin Kaiser, Wei Fun Lo, Abdol Majid Riahi, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2006
Angiogenesis in multiple myelomaChristian Jakob, Jan Sterz, Ivana Zavrski, et al.
Organic Letters|July 28, 2007
A general copper-catalyzed sulfonylation of arylboronic acidsAnirban Kar, Iliyas Ali Sayyed, Wei Fun Lo, et al.
BMJ Open|October 26, 2022
MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myelomaJessica Kendall, Andrew Hall, Sadie Roberts, et al.
Haematologica|February 8, 2006
The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myelomaMartin Kaiser, Ivana Zavrski, Jan Sterz, et al.
Annals of Human Genetics|February 16, 2019
Regions of homozygosity as risk factors for multiple myelomaMolly Went, Amit Sud, Ni Li, et al.
The British Journal of Radiology|March 18, 2021
Repeatability and reproducibility of apparent diffusion coefficient and fat fraction measurement of focal myeloma lesions on whole body magnetic resonance imagingTara Barwick, Matthew Orton, Dow Mu Koh, et al.
British Journal of Haematology|January 18, 2021
A real-world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple-myeloma patientsSarah Bird, Charlotte Pawlyn, Susanna Nallamilli, et al.
BMC Cancer|April 2, 2020
Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myelomaPriya Sriskandarajah, Alexis De Haven Brandon, Kenneth MacLeod, et al.
Pageof 16